CBP-1008-01

A multi-center, open-label, first-in-human, phase Ia and Ib study for evaluation of the safety, tolerability, and pharmacokinetic profile of CBP-1008 for Injection in patients with advanced malignant solid tumors, with expansions in selected indications.

Locations


Beijing Cancer Hospital


Beijing,China

Recruiting


Fudan University Shanghai Cancer Center


Shanghai,China

Recruiting


Cancer Hospital Chinese Academy of Medical Sciences


Beijing,China

Recruiting


Sun Yat-sen Memorial Hospital


Guangzhou,China

No longer available


The Second Affiliated Hospital of Zhejiang University School of Medicine


Hangzhou,China

Recruiting


Sir Run Run Shaw Hospital of Zhejiang University School of Medicine


Hangzhou,China

Recruiting


Tianjin Medical University Cancer Institute&Hospital


Tianjin,China

No longer available


The First Affiliated Hospital of Zhejiang University School of Medicine


Hangzhou,China

Recruiting


Henan Cancer Hospital


Zhengzhou,China

Recruiting


The First Affiliated Hospital of Xiamen University


Xiamen,China

No longer available


Harbin Medical University Cancer Hospital


Harbin,China

Recruiting


Hunan Cancer Hospital


Changsha,China

Recruiting


Qilu Hospital of Shandong University


Jinan,China

Recruiting


Hubei Cancer Hospital


Wuhan,China

Recruiting


Linyi Cancer Hospital


Linyi,China

No longer available


The Second Affiliated Hospital of Suzhou University


Suzhou,China

No longer available


Beijing Obstetrics and Gynecology Hospital


Beijing,China

Recruiting


Union Hospital, Tongji Medical College, Huazhong University of Science and Technology


Wuhan,China

Recruiting


Jilin Cancer Hospital


Jilin,China

Recruiting


Tongji Hospital of Tongji University


Shanghai,China

No longer available


The Second Affiliated Hospital of Chongqing Medical University


Chongqing,China

Recruiting


The First Affiliated Hospital of Zhengzhou University


Zhengzhou,China

Recruiting


Zhejiang Cancer Hospital


Hangzhou,China

Recruiting